Study of Tissue Samples From Patients With Glioma or Other Brain Tumors

This study has been completed.
Information provided by (Responsible Party):
University Hospital, Montpellier Identifier:
First received: August 26, 2009
Last updated: November 23, 2015
Last verified: November 2015

RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at tissue samples from patients with glioma or other brain tumors.

Condition Intervention
Central Nervous System Lymphoma
Other: laboratory biomarker analysis
Other: pharmacogenomic studies

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Identification of Genes Involved in the Pathogenesis of Gliomas by Transcriptome Analysis

Resource links provided by NLM:

Further study details as provided by University Hospital, Montpellier:

Primary Outcome Measures:
  • Pathophysiology of gliomas [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    Pathophysiology of gliomas that may predict prognosis and progression or that could identify new therapeutic

Secondary Outcome Measures:
  • Identification of molecular [ Time Frame: 1 day ] [ Designated as safety issue: No ]
    Identification of molecular markers that may predict prognosis and progression or that could identify new therapeutic

Enrollment: 180
Study Start Date: November 2003
Study Completion Date: November 2015
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: laboratory biomarker analysis
    laboratory biomarker analysis
    Other: pharmacogenomic studies
    pharmacogenomic studies
Detailed Description:



  • To better understand the pathophysiology of gliomas and identify molecular markers that may predict prognosis and progression or that could identify new therapeutic approaches.


  • To compare gene expression profiles, in terms of response to treatment, and attempt to isolate subgroups of patients with objective response to certain types of chemotherapy or radiotherapy.

OUTLINE: This is a multicenter study.

Biological samples are collected from patients at time of surgery for diagnostic and/or treatment purposes.


Ages Eligible for Study:   18 Years to 120 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Pathophysiology of gliomas and identification of molecular markers that may predict prognosis and progression or that could identify new therapeutic

Inclusion Histologically confirmed glioma of any grade or rare primary brain tumor No urgent situation No known or suspected active infection Must not be deprived of liberty or protected by law Not pregnant or nursing

Exclusion :

No concurrent participation in other trials that require a period of exclusion

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00967200

CHU Montpellier
Montpellier, France, 34295
Clinique Gui de Chauliac
Montpellier, France, 34295
Sponsors and Collaborators
University Hospital, Montpellier
Principal Investigator: Luc Bauchet, MD University Hospital, Montpellier
  More Information

No publications provided

Responsible Party: University Hospital, Montpellier Identifier: NCT00967200     History of Changes
Other Study ID Numbers: 7745
Study First Received: August 26, 2009
Last Updated: November 23, 2015
Health Authority: France: Commission nationale de l'informatique et des libertés

Keywords provided by University Hospital, Montpellier:
adult anaplastic astrocytoma
adult diffuse astrocytoma
adult glioblastoma
adult giant cell glioblastoma
adult gliosarcoma
adult pilocytic astrocytoma
adult pineal gland astrocytoma
adult subependymal giant cell astrocytoma
adult brain stem glioma
adult choroid plexus tumor
adult craniopharyngioma
adult ependymoblastoma
adult medulloblastoma
adult supratentorial primitive neuroectodermal tumor (PNET)
adult anaplastic ependymoma
adult ependymoma
adult myxopapillary ependymoma
adult subependymoma
meningeal melanocytoma
adult meningeal hemangiopericytoma
adult grade I meningioma
adult grade II meningioma
adult anaplastic meningioma
adult papillary meningioma
adult anaplastic oligodendroglioma
adult oligodendroglioma
adult pineoblastoma
adult pineocytoma
adult mixed glioma
recurrent adult brain tumor processed this record on November 25, 2015